Cardiac resynchronization therapy for patients with mild to moderately reduced ejection fraction and left bundle branch block
Authors:
- 19 May 2024
- journal article
- research article
- Published by Elsevier in Heart Rhythm
- Vol. 21 (11) , 2250-2259
Abstract
No abstract availableKeywords
Funding Information
- U.S. Food and Drug Administration
- NIH (R01HL134864)
This publication has 34 references indexed in Scilit:
- Risk of malignant ventricular arrhythmias in patients with mildly to moderately reduced ejection fraction after permanent pacemaker implantationHeart Rhythm, 2024
- 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failureHeart Rhythm, 2023
- Association of left ventricular remodeling with cardiac resynchronization therapy outcomesHeart Rhythm, 2022
- Association of interventricular activation delay with clinical outcomes in cardiac resynchronization therapyHeart Rhythm, 2022
- Cardiac resynchronization therapy in patients with heart failure and moderately reduced ejection fraction: Could it trigger a super-response?Indian Heart Journal, 2019
- Age, Prognostic Impact of QRS Prolongation and Left Bundle Branch Block, and Utilization of Cardiac Resynchronization Therapy: Findings from 14 713 Patients in the Swedish Heart Failure RegistryEuropean Journal of Heart Failure, 2014
- A Metric for Evaluating the Cardiac Response to Resynchronization TherapyThe American Journal of Cardiology, 2014
- Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure SymptomsJACC, 2008
- Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart FailureJACC, 2007
- Burden of Systolic and Diastolic Ventricular Dysfunction in the CommunityJAMA, 2003